Blueprint Medicines Corporation discovered GAVRETO™ for the treatment of adult patients with metastatic Rearranged during Transfection (RET) fusion-positive Non-small Cell Lung Cancer (NSCLC).
GAVRETO an oral, RET-targeted therapy is taken daily twice. The oral therapy is designed to selectively and potently inhibit RET alterations which gives rise to many types of cancers, including approximately 1 to 2 percent of patients with NSCLC.
GAVRETO™ oral therapy makes a potential benefit in changing standards of care for patients with RET fusion-positive non-small cell lung cancer, where the treatments for patients are limited.
Some of the major side effects with GAVRETO include interstitial lung disease/pneumonitis, hypertension, hepatotoxicity, hemorrhagic events, risk of impaired wound healing and risk of embryo-fetal toxicity.
U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of adult patients with metastatic RET fusion-positive Non-small Cell Lung Cancer (NSCLC).